To address the question of whether it might be feasible to use SnMP to enrich tumor-specific T cells in a clinical environment, we used the IFN-γ cytokine secretion assay (CSA) comparable to the cytokine capture system (CCS) used for the enrichment of clinical grade T cells for adoptive T-cell transfer. Here, IFNG is linked to neoplasm.